The Tres Cantos Open Lab Foundation announced today the funding of a one-year project with the University of Helsinki to work on a series of benzimidazoles active against Plasmodium falciparum (Pf). Previously, these molecules have shown activity against protozoan parasites indicating that they carry a very versatile chemical scaffold. Linked to this investigation and after an analogue search of the GSK’s antimalarial collection (TCAMS) some new antiplasmodial compounds were found to show activity at 1 μM. The team plan to work on studying SAR with the help of in silico methods, search of TCAMS compounds and chemical optimization. The aim is finding a lead that shows therapeutic efficacy.
“Evaluation of preclinical properties is not straightforward in the current academic setting. This project will clearly benefit from the whole GSK’s drug discovery capacity. The possibility to create ADME profile of the optimized molecules will open up a way to find new antimalarials” said Dr Jari Yli-Kauhaluoma, professor of medicinal chemistry at the University of Helsinki.
About the Tres Cantos Open Lab Foundation
The Tres Cantos Open Lab Foundation is focused on providing funding and support for scientists, academics and institutions to develop and advance new ideas that could lead to new medicines to treat diseases of the developing world. Researchers are invited to submit projects for collaboration and funding, to be reviewed by the Foundation’s Governing Board and Trustees.
About the University of Helsinki
The University of Helsinki was founded in 1640. It is one of the best multidisciplinary research universities in the world. The high-quality research creates new knowledge for educating specialists in various fields as well as for utilisation in social decision-making and the business sector.
The University of Helsinki is an active, international academic community of 40,000 students and staff members. It operates on four campuses in Helsinki and at 17 other locations.